729 related articles for article (PubMed ID: 15270878)
1. Increased advanced oxidation protein products in Behçet's disease: a new activity marker?
Yazici C; Köse K; Caliş M; DemIr M; Kirnap M; Ateş F
Br J Dermatol; 2004 Jul; 151(1):105-11. PubMed ID: 15270878
[TBL] [Abstract][Full Text] [Related]
2. Protein oxidation status in patients with ankylosing spondylitis.
Yazici C; Köse K; Calis M; Kuzugüden S; Kirnap M
Rheumatology (Oxford); 2004 Oct; 43(10):1235-9. PubMed ID: 15292529
[TBL] [Abstract][Full Text] [Related]
3. Investigation of protein oxidation and lipid peroxidation in patients with rheumatoid arthritis.
Baskol G; Demir H; Baskol M; Kilic E; Ates F; Karakukcu C; Ustdal M
Cell Biochem Funct; 2006; 24(4):307-11. PubMed ID: 16142689
[TBL] [Abstract][Full Text] [Related]
4. Levels of soluble E-selectin in patients with active Behcet's disease.
Sari RA; Kiziltunç A; Taysi S; Akdemir S; Gündoğdu M
Clin Rheumatol; 2005 Feb; 24(1):55-9. PubMed ID: 15338451
[TBL] [Abstract][Full Text] [Related]
5. Adenosine deaminase enzyme activity is increased and negatively correlates with catalase, superoxide dismutase and glutathione peroxidase in patients with Behçet's disease: original contributions/clinical and laboratory investigations.
Erkiliç K; Evereklioglu C; Cekmen M; Ozkiris A; Duygulu F; Dogan H
Mediators Inflamm; 2003 Apr; 12(2):107-16. PubMed ID: 12775361
[TBL] [Abstract][Full Text] [Related]
6. Serum oxidant/antioxidant status in patients with Behçet's disease.
Taysi S; Kocer I; Memisogullari R; Kiziltunc A
Ann Clin Lab Sci; 2002; 32(4):377-82. PubMed ID: 12458889
[TBL] [Abstract][Full Text] [Related]
7. Significance of serum interleukin-8 levels in patients with Behcet's disease: high levels may indicate vascular involvement.
Durmazlar SP; Ulkar GB; Eskioglu F; Tatlican S; Mert A; Akgul A
Int J Dermatol; 2009 Mar; 48(3):259-64. PubMed ID: 19261013
[TBL] [Abstract][Full Text] [Related]
8. Nitric oxide, lipid peroxidation and antioxidant defence system in patients with active or inactive Behçet's disease.
Buldanlioglu S; Turkmen S; Ayabakan HB; Yenice N; Vardar M; Dogan S; Mercan E
Br J Dermatol; 2005 Sep; 153(3):526-30. PubMed ID: 16120137
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of allantoin levels as a new marker of oxidative stress in Behçet's disease.
Yardim-Akaydin S; Sepici A; Ozkan Y; Simşek B; Sepici V
Scand J Rheumatol; 2006; 35(1):61-4. PubMed ID: 16467045
[TBL] [Abstract][Full Text] [Related]
10. A novel approach in psoriasis: first usage of known protein oxidation markers to prove oxidative stress.
Yazici C; Köse K; Utaş S; Tanrikulu E; Taşlidere N
Arch Dermatol Res; 2016 Apr; 308(3):207-12. PubMed ID: 26842230
[TBL] [Abstract][Full Text] [Related]
11. Systemic levels of the T cell regulatory cytokines IL-10 and IL-12 in Bechçet's disease; soluble TNFR-75 as a biological marker of disease activity.
Turan B; Gallati H; Erdi H; Gürler A; Michel BA; Villiger PM
J Rheumatol; 1997 Jan; 24(1):128-32. PubMed ID: 9002023
[TBL] [Abstract][Full Text] [Related]
12. Plasma homocysteine level and uveitis in Behçet's disease.
Okka M; Oztürk M; Kockar MC; Bavbek N; Rasier Y; Gunduz K
Isr Med Assoc J; 2002 Nov; 4(11 Suppl):931-4. PubMed ID: 12455183
[TBL] [Abstract][Full Text] [Related]
13. Respective role of uraemic toxins and myeloperoxidase in the uraemic state.
Capeillère-Blandin C; Gausson V; Nguyen AT; Descamps-Latscha B; Drüeke T; Witko-Sarsat V
Nephrol Dial Transplant; 2006 Jun; 21(6):1555-63. PubMed ID: 16476719
[TBL] [Abstract][Full Text] [Related]
14. Further evidence of inflammation in chronic rheumatic valve disease (CRVD): high levels of advanced oxidation protein products (AOPP) and high sensitive C-reactive protein (hs-CRP).
Chiu-Braga YY; Hayashi SY; Schafranski M; Messias-Reason IJ
Int J Cardiol; 2006 May; 109(2):275-6. PubMed ID: 15946754
[TBL] [Abstract][Full Text] [Related]
15. Peripheral insulin resistance in patients with Behçet's disease.
Erdem H; Dinc A; Pay S; Simsek I; Turan M
J Eur Acad Dermatol Venereol; 2006 Apr; 20(4):391-5. PubMed ID: 16643134
[TBL] [Abstract][Full Text] [Related]
16. Homocysteine: an activity marker in Behçet's disease?
Sarican T; Ayabakan H; Turkmen S; Kalaslioglu V; Baran F; Yenice N
J Dermatol Sci; 2007 Feb; 45(2):121-6. PubMed ID: 17182219
[TBL] [Abstract][Full Text] [Related]
17. Elevated serum granulocyte colony-stimulating factor levels in patients with active phase of sweet syndrome and patients with active behcet disease: implication in neutrophil apoptosis dysfunction.
Kawakami T; Ohashi S; Kawa Y; Takahama H; Ito M; Soma Y; Mizoguchi M
Arch Dermatol; 2004 May; 140(5):570-4. PubMed ID: 15148101
[TBL] [Abstract][Full Text] [Related]
18. Increased level of advanced oxidation products (AOPP) as a marker of oxidative stress in patients with acute coronary syndrome.
Skvarilová M; Bulava A; Stejskal D; Adamovská S; Bartek J
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2005 Jun; 149(1):83-7. PubMed ID: 16170393
[TBL] [Abstract][Full Text] [Related]
19. The relationship between serum prolactin levels and disease activity in patients with Behcet's disease.
Atasoy M; Karatay S; Yildirim K; Kadi M; Erdem T; Senel K
Cell Biochem Funct; 2006; 24(4):353-6. PubMed ID: 15898123
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of nitrosative and oxidative stress in Behçet disease.
Bekpinar S; Kiliç N; Unlüçerçi Y; Akdag-Köse A; Azizlerli G; Ozbek-Kir Z
J Eur Acad Dermatol Venereol; 2005 Mar; 19(2):167-71. PubMed ID: 15752284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
